In this section
Treosulfan for bone marrow transplant for nonmalignant diseases
Children’s Hospital of Wisconsin is currently enrolling patients on a Phase II clinical trial of Treosulfan, which is used in combination with other chemotherapy drugs in patients with nonmalignant diseases treatable by allogeneic transplant, including:
- Sickle Cell Disease
- Bone Marrow Failure Syndromes
- Diamond-Blackfan Anemia
- Dyskeratosis Congenita
- Primary Immunodeficiencies
Children’s Hospital is one of only two sites in the country where this trial is available. We are participating in collaboration with The Fred Hutchinson Cancer Research Center in Seattle.
Being picked to participate in this select study is evidence of our transplant program’s dedication and expertise. Our program is FACT (Foundation for the Accreditation of Cellular Therapy) accredited and has performed over 1,100 bone marrow transplants. Children’s also ranked in 9 specialty areas in the U.S. News & World Report Best Children’s Hospitals list.
For more information
Information about this trial is also available at www.clinicaltrials.gov NCT00919503.